Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Impaired Fasting Glucose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    106 result(s) found for: Impaired Fasting Glucose. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2006-005772-41 Sponsor Protocol Number: LIMIT phase 2 version 1.0 Start Date*: 2006-12-05
    Sponsor Name:investigator-driven research: Erasmus MC, Neurovascular Section
    Full Title: LIMIT: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose tolerance and a recent TIA or minor ischemic stroke: a phase 2, randomized, controlled trial
    Medical condition: Patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052426 Glucose intolerance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004497-40 Sponsor Protocol Number: METIGT2008 Start Date*: 2008-11-11
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo
    Medical condition: Impaired fasting glucose
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056997 Impaired fasting glucose LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003483-59 Sponsor Protocol Number: CVAL489A2429 Start Date*: 2006-12-18
    Sponsor Name:VU University Medical Centre
    Full Title: PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects; A 52-week randomized controlled factorial study in subjects with impaired fasting glucose and/or im...
    Medical condition: subjects with impaired fasting glucose (IFG; blood glucose > or = 5.6 and < 7 mmol/l) and/or impaired glucose tolerance (IGT; 2-h post-load glucose 7.8-11.1 mmol/l).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018429 Glucose tolerance impaired LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000899-40 Sponsor Protocol Number: Guid/05/Met-GDM/001 Start Date*: 2006-08-28
    Sponsor Name:GUIDOTTI
    Full Title: ASSESSMENT OF EFFECTS OF A 12-MONTH TREATMENT WITH METFORMIN ON INSULIN ACTION AND SECRETION IN WOMEN WITH PRIOR GESTATIONAL DIABETES MELLITUS (GDM)
    Medical condition: previous gestational diabetes (GDM) and altered glucose metabolism in the post-partum period (Impaired Fasting Glucose or Impaired Gluocse Tolerance)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018429 Glucose tolerance impaired PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000823-15 Sponsor Protocol Number: DIASA3 Start Date*: 2019-10-18
    Sponsor Name:Oslo University Hospital
    Full Title: Glucose metabolism in South Asian women with impaired glucose tolerance or impaired fasting glucose. DIAbetes in South Asians – DIASA 3 A 12-week intervention trial with oral antidiabetic medicati...
    Medical condition: Pre-diabetes in women of South Asian ethnicity. Women of South Asian ethnicity with previous gestational diabetes, where pre-diabetes in the form of impaired glucose tolerance or impaired fasting ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000940-28 Sponsor Protocol Number: Final Protocol version 6 Start Date*: 2007-11-28
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: The Rimonabant in treatment of Prediabetes Study: a randomised clinical trial of Rimonabant in the treatment of patients with Prediabetes
    Medical condition: Impaired Glucose tolerance and Impaired fasting Glycaemia (Together known as Prediabetes)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000146 Abnormal glucose tolerance test (excl DM) LLT
    9.1 10056997 Impaired fasting glucose LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024487-18 Sponsor Protocol Number: DvitamininDM2_v1 Start Date*: 2011-06-20
    Sponsor Name:Dept. of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital
    Full Title: Effects of vitamin D on beta cell function and insulin sensitivity in pre-diabetes and diabetes mellitus type 2 - EVIDENS
    Medical condition: Impaired glucose tolerance, impaired fasting glucose and type 2 diabetes mellitus. Vitamin D deficiency.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10018429 Glucose tolerance impaired PT
    13.1 10027433 - Metabolism and nutrition disorders 10056997 Impaired fasting glucose PT
    13.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    13.1 10027433 - Metabolism and nutrition disorders 10047626 Vitamin D deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002766-73 Sponsor Protocol Number: PHT/2014/44 Start Date*: 2015-10-26
    Sponsor Name:Portsmouth Hospitals NHS Trust
    Full Title: The effect of oral Vitamin D supplementation on endothelial function, vascular inflammation, oxidative stress and insulin sensitivity in patients with impaired fasting glucose: A randomised, double...
    Medical condition: Impaired fasting glycaemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10046242 Unspecified vitamin D deficiency LLT
    18.0 10027433 - Metabolism and nutrition disorders 10056997 Impaired fasting glucose PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003532-39 Sponsor Protocol Number: SitaBAT01 Start Date*: 2014-11-24
    Sponsor Name:Leiden University Medical Center
    Full Title: The effect of sitagliptin on brown adipose tissue and whole-body metabolism in overweight pre-diabetic men
    Medical condition: Obesity, dyslipidemia and impaired glucose tolerance
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-003803-30 Sponsor Protocol Number: 2560/2008 Start Date*: 2011-04-28
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Effects of the treatment with metformin and/or sitagliptin on β- cell function and insulin resistance in women with prior gestational diabetes.
    Medical condition: previous gestational diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000137 LLT
    9.1 10056997 LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005980-26 Sponsor Protocol Number: MAAS Start Date*: 2012-07-04
    Sponsor Name:
    Full Title: Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial
    Medical condition: Stroke Transient ischemic attack Impaired glucose tolerance
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    14.1 10027433 - Metabolism and nutrition disorders 10052426 Glucose intolerance LLT
    14.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    14.1 10029205 - Nervous system disorders 10044391 Transient ischemic attacks LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003283-31 Sponsor Protocol Number: NL67170.068.18 Start Date*: 2019-03-13
    Sponsor Name:School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University
    Full Title: MaasFlex: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Ox...
    Medical condition: Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001711-30 Sponsor Protocol Number: RIMON_R_00961 Start Date*: 2006-10-11
    Sponsor Name:sanofi aventis Groupe
    Full Title: A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fast...
    Medical condition: abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) CZ (Completed) SI (Completed) FR (Completed) NL (Prematurely Ended) NO (Completed) FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) HU (Completed) SK (Completed) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002230-37 Sponsor Protocol Number: CLAF237ANL05T Start Date*: 2013-12-19
    Sponsor Name:Erasmus Medical Center
    Full Title: “Novel Approach to Detect the Detailed Effects of Vildagliptin on Beta-cell Dynamics in Patients with Early-onset Type 2 Diabetes”
    Medical condition: impaired fasting glucose/impaired glucose tolerance, prediabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002997-31 Sponsor Protocol Number: SCH/05/015 Start Date*: 2006-08-10
    Sponsor Name:Sheffield Children's NHS Trust
    Full Title: A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis.
    Medical condition: Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. E...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003101-53 Sponsor Protocol Number: ARTinMMS Start Date*: 2007-01-10
    Sponsor Name:Karolinska Institutet
    Full Title: A randomised placebo controlled study of transdermal testosterone therapy (testosterone 1% hydroalcohol gel) to investigate the efficacy and safety in men with abdominal obesity, low testosterone l...
    Medical condition: The metabolic syndrome constitutes a cluster of risk factors for cardiovascular disease with increased morbidity and mortality. The metabolic syndrome is referred to as a concomitant occurrence of ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001888-29 Sponsor Protocol Number: 0816-2007 Start Date*: 2007-11-19
    Sponsor Name:University of Leipzig
    Full Title: Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.
    Medical condition: severe cardiovascular artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018708-99 Sponsor Protocol Number: 1245.39 Start Date*: 2010-10-19
    Sponsor Name:BOEHRINGER ING.
    Full Title: An open-label, phase IIb study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor ...
    Medical condition: patients with IGT or type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 LLT
    9.1 10018429 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016022-14 Sponsor Protocol Number: PREVORAL 2 Start Date*: 2009-09-29
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: Studio aperto per la valutazione dell efficacia dell insulina spray buccale sul controllo glicometabolico in soggetti con ridotta tolleranza ai carboidrati (studio PREVORAL 2).
    Medical condition: impaired glucose tolerance (IGT)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020638 Hyperglycaemic conditions NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000121-31 Sponsor Protocol Number: PSYK-TREAT-HEALTHY Start Date*: 2013-03-20
    Sponsor Name:Prof., dr. med. Anders Fink-Jensen
    Full Title: Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients?
    Medical condition: Dysglycaemia, schizophrenia, paranoid psycosis, schizotypal disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 23:32:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA